Equity Investments at a Premium in Biotech Licensings
Executive Summary
Alliance Watch focuses on alliances between established drug firms and public biotechs in which the larger partner bought equity at a premium to the company's average trading price for the 10 days prior to the deal's announcement.You may also be interested in...
‘Supplement’ On CBD Product Label A Bullseye For US Litigants, Says Attorney
Two CBD marketers warned by FDA in a recent crackdown are targeted in class action complaints alleging they made unsubstantiated health claims and mislabeled ‘illegal drug’ products as supplements. Complaints are a wake-up call to CBD wellness industry to ensure claims are substantiated, as the class action bar is on the prowl following the agency’s 15 warning letter blast in November.
HBW Market News: GNC US Chief, Clasado Commercial Head, Barentz Funding
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
US Government Drug Pricing ‘Negotiation:’ Where We Go From Here
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports